Publications Olgotrelvir, A Dual Inhibitor of SARS-CoV-2 Mpro and Cathepsin L, as a Standalone Antiviral Oral Intervention Candidate for COVID-19 30 June 2025 /images/2025/SARVS-CoV-2_Inhibitor_Olgotrelvir.pdf Previous article: Structure-based Design of Pyridone−Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition Prev Next article: Molecular Recognition by Glycoside Pseudo Base Pairs and Triples in an Apramycin–RNA Complex Next
